*Applications will be reviewed on a rolling-basis, and this opportunity will remain open until filled.
A research opportunity is currently available in the Division of Cellular and Gene Therapies, in the Office of Tissues and Advanced Therapies (OTAT) at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.
The research is focused on understanding the emerging vector-borne disease pathogenesis such as tick-borne diseases. The first project will focus on the identification and detection of vector-borne pathogens e.g. Powassan virus, Rickettsia, etc., in the patient samples and understand the disease pathogenesis. The participant will use advanced tools such as human organs-on-chip and next-generation sequencing assays to better understand the disease pathogenesis in humans. Further, the participant will get the opportunity to train other individuals, attend conferences, present research findings, etc.
Anticipated Appointment Start Date: As soon as a qualified candidate is identified; start date is flexible
This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.
If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity (FDA-CBER-2021-0042) in your email.